Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
SXTP · NASDAQ · Pharmaceutical Preparations
60 Degrees Pharmaceuticals (SXTP) · oqro.io/stocks/SXTP · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$0.5179−0.001 (−0.19%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
No open-market purchase by an insider of 60 Degrees Pharmaceuticals was filed in the last 90 days. The latest on record was on Jun 16, 2026.
Since 2024, 60 Degrees Pharmaceuticals insiders reported 22 open-market purchases and 0 sales on Forms 4 and 5, with purchases in 3 different years, most recently 2026.
No open-market sale by an insider of 60 Degrees Pharmaceuticals (SXTP) was filed with the SEC in the last 90 days.
No trade in 60 Degrees Pharmaceuticals (SXTP) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−88.9% (−$4.16) from Nov 13, 2025 to Nov 13, 2026 · adjusted daily closes
Adjusted close went from $4.68 on Nov 13, 2025 to $0.5179 on Nov 13, 2026 (−88.9%). Disclosed in this range: 4 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Washington, Dc.
Last 12 months
−88.9%
Market value
$1.82M
S&P 500 +12.3% over the same dates. Prices adjusted for splits and dividends.
Short interest: 255K shares sold short (7.3% of shares outstanding), +88.4% vs the previous count, 1.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$208K
+106.0% vs the same quarter a year earlier
Free cash flow, last 12 months
−$8.89M
This quarter −$2.23M, a year earlier −$1.5M
Net cash
$873K
Debt $150K, cash $1.02M, at Jun 30, 2026
Net income, last 12 months
−$8.11M
Operating profit covers interest -1134.8x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO.
Revenue, fiscal 2025
$1.01M
+65.5% vs the year before
Net income, fiscal 2025
−$7.37M
A loss for the year
Shares outstanding
3.52M
As of Aug 14, 2026
Insider buying
Traded Jun 12 · filed 4 days later
Since the trade −61.9% · S&P 500 +1.7% · to Nov 13
The CEO of 60 Degrees Pharmaceuticals paid $10K out of pocket for 60 Degrees Pharmaceuticals shares. It was the first purchase in 6 months. Shares held went up 44% with this purchase.
Insider buying
Traded Dec 15, 2025 · filed 2 days later
Since the trade −84.2% · S&P 500 +10.8% · to Nov 13
The CEO of 60 Degrees Pharmaceuticals paid $7.8K out of pocket for 60 Degrees Pharmaceuticals shares. Shares held went up 19% with this purchase.
Traded Dec 10 – Dec 11, 2025 · largest single transaction ~$8.9K
Dec 10, 2025~$8.9K · 9,350 sh @ $0.9504
DetailsOfficial recordDec 11, 2025~$3.3K · 3,613 sh @ $0.9184
DetailsOfficial recordInsider buying
Traded Jun 3, 2025 · filed 3 days later
Since the trade −95.5% · S&P 500 +26.6% · to Nov 13
A 60 Degrees Pharmaceuticals director paid $8.6K out of pocket for 60 Degrees Pharmaceuticals shares. It was the first purchase in 6 months. Shares held went up 28% with this purchase.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Mitchell P. Kopin
Schedule 13G: passive · filed Nov 10, 2026 · 390K shares
Orca Capital AG
Schedule 13G: passive · filed Nov 12, 2026 · 223K shares
Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.
0 active phase 3 trials and 2 active phase 2 trials led by this company, mostly in chronic babesiosis, babesiosis. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Insiders of 60 Degrees Pharmaceuticals reported 22 open-market purchases and 0 sales since 2024; purchases in 3 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $10K1×1 trade | — |
| 2025 | $34K5×5 trades | — |
| 2024 | $212K16×16 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Notice of delisting or failure to meet listing rules
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.